<DOC>
	<DOCNO>NCT01790932</DOCNO>
	<brief_summary>This research study Phase II clinical trial . Phase II clinical trial test effectiveness investigational drug learn whether drug work treat specific cancer . `` Investigational '' mean drug still study research doctor try find it-such safest dose use , side effect may cause , drug effective treat different type cancer . It also mean FDA yet approve BKM120 use patient , include people type cancer . BKM120 drug work block protein call PI3K may contribute cancer growth . This drug use experiment laboratory information research study suggest BKM120 may help prevent cancer cell grow . In research study , investigator look see BKM120 work stop breast cancer cell grow .</brief_summary>
	<brief_title>BKM120 For Triple Negative Breast Cancer</brief_title>
	<detailed_description>If agree participate research study ask undergo test procedure confirm eligibility . Many test procedure likely part regular cancer care may do even turn take part research study . If test procedure recently , may may repeat . These test procedure include : medical history , physical examination , vital sign , self-rated mood questionnaire , assessment tumor , blood test , serum pregnancy test , urine test electrocardiogram . If test show eligible participate research study , begin study treatment . If meet eligibility criterion , able participate research study . The following additional research procedure perform time study screening : research blood sample tumor tissue collection previous biopsy surgery . If take part research study , give study drug-dosing calendar treatment cycle . Each treatment cycle last 28 day time take study drug BKM120 per day . You take BKM120 every day teh morning approximately time . You required keep drug diary study . Please bring drug diary every clinic visit . During Cycle 1 Cycle 2 , come clinic every two week undergo several test order evaluate health status see tolerate treatment , well evaluate symptom may . For cycle thereafter , come clinic month every 4 week . Evaluations blood sample physical assessment may lead change study treatment . On Day 1 every Cycle Day 15 Cycle 1 2 undergo following : vital sign , physical examination , blood test , two self-rated mood questionnaire , uring test , scan ( image test ) , tumor biopsy . You return end treatment visit approximately 7 day stop study medication . At visit follow assessment perform : vital sign , physical examination , blood test , research blood sample , urine test , two self-rated mood questionnaire , electrocardiogram tumor biopsy . If stop study medication reason condition worsening , member research study staff contact physician every 3 month total 2 year discontinuation study treatment , order obtain information additional therapy receive disease , disease evolving . If terminate study treatment early research study 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Pathologically radiologically confirm metastatic triple negative breast cancer Up two prior line chemotherapy metastatic breast cancer Availability representative tumor specimen At least one measurable lesion Have receive previous treatment PI3K inhibitor Symptomatic CNS metastasis ( control asymptomatic CNS metastasis acceptable ) Concurrent malignancy malignancy within 3 year study enrollment Any follow mood disorder : active major depressive episode , bipolar disorder , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation , great equal CTCAE grade 3 anxiety Concurrently use approve investigational antineoplastic agent and/or chemotherapy within 21 day prior enrollment study Has receive radiation therapy within 28 day prior enrollment study recover side effect therapy Major surgery within 28 day start therapy recover major side effect previous surgery Poorly control diabetes mellitus History cardiac dysfunction Currently receive treatment QT prolong medication treatment discontinue switched different medication Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 Receiving chronic treatment steroid another immunosuppressive agent Other concurrent severe and/or uncontrolled medical condition would contraindicate participation study History noncompliance medical regimen Currently treat drug know moderate strong inhibitor inducer isoenzyme CYP3A Known history HIV Pregnant breastfeed Unwilling observe total abstinence use double barrier method birth control throughout trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Triple Negative</keyword>
</DOC>